Evidence map›Paper›PMID 36144459›Full record

ArticleMicroorganisms2022

Strong Biofilm Formation and Low Cloxacillin Susceptibility in Biofilm-Growing CC398

Nathalie van der Mee-Marquet, Sandra Dos Santos, Seydina M Diene, Isabelle Duflot, Laurent Mereghetti, Anne-Sophie Valentin, Patrice François, On Behalf Of The Spiadi Collaborative Group

Open access · goldAbstract read
In one paragraph

Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Nathalie van der Mee-MarquetCentre d'Appui pour la Prévention des Infections Associées aux Soins (CPias) de la Région Centre Val de Loire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, 37044 Tours, France.ORCID 0000-0003-2766-6630
Sandra Dos SantosCentre d'Appui pour la Prévention des Infections Associées aux Soins (CPias) de la Région Centre Val de Loire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, 37044 Tours, France.
Seydina M DieneFaculté de Pharmacie, Microbes Evolution Phylogeny and Infections, IHU-Méditerranée Infection, Aix-Marseille Université, 13005 Marseille, France.ORCID 0000-0002-6466-2324
Isabelle DuflotCentre d'Appui pour la Prévention des Infections Associées aux Soins (CPias) de la Région Centre Val de Loire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, 37044 Tours, France.
Laurent MereghettiService de Bactériologie, Virologie et Hygiène, Hôpital Trousseau, Centre Hospitalier Régional Universitaire, 37044 Tours, France.
Anne-Sophie ValentinCentre d'Appui pour la Prévention des Infections Associées aux Soins (CPias) de la Région Centre Val de Loire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, 37044 Tours, France.ORCID 0000-0001-8662-097X
Patrice FrançoisDepartment of Medicine, University of Geneva Hospitals, 1205 Geneva, Switzerland.ORCID 0000-0002-0540-750X
On Behalf Of The Spiadi Collaborative Group
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement · FRCentre Hospitalier Universitaire de Tours · FRAix-Marseille Université · FRUniversity of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A prospective 3-month study carried out in 267 ICUs revealed an S. aureus nosocomial bacteremia in one admitted patient out of 110 in adult and pediatric sectors, and in one out of 230 newborns; 242 S. aureus bacteremias occurred during the study, including 7.9% MRSA-bacteremias. In one ICU out of ten, the molecular characteristics, antimicrobial susceptibility profiles and biofilm production of the strains responsible for S. aureus bacteremia were studied. Of the 53 strains studied, 9.4% were MRSA and 52.8% were resistant to erythromycin. MLST showed the predominance of CC398 (37.7% of the strains) followed by CC8 (17.0%), CC45 (13.2%) and CC30 (9.4%). The lukF/S genes were absent from our isolates and tst-1 was found in 9.4% of the strains. Under static conditions and without exposure to glucose, biofilm production was rare (9.4% of the strains, without any CC398). The percentage increased to 62.3% for strains grown in broth supplemented with 1% glucose (including 7 out of 9 CC8 and 17 out of the 20 CC398). Further study of the CC398, including whole genome sequencing, revealed (1) highly frequent patient death within seven days after CC398 bacteremia diagnosis (47.4%), (2) 95.0% of the strains producing biofilm when exposed to sub-inhibitory concentrations of cloxacillin, (3) a stronger biofilm production following exposure to cloxacillin than that observed in broth supplemented with glucose only (p < 0.001), (4) a high minimum biofilm eradication concentration of cloxacillin (128 mg/L) indicating a low cloxacillin susceptibility of biofilm-growing CC398, (5) 95.0% of the strains carrying a ϕSa-3 like prophage and its particular evasion cluster (i.e., yielding chp and scin genes), and (6) 30.0% of the strains carrying a ϕMR11-like prophage and yielding a higher ability to produce biofilm. Our results provide evidence that active surveillance is required to avoid spreading of this virulent staphylococcal clone.

Indexed as

antibiotic tolerancebacteremiabiofilmCC398cloxacillinintensive careStaphylococcus aureus

Identifiers

PMID36144459
PMCPMC9504214
OpenAlexW4296365888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.